We are studying the mechanisms that increase the risk of type 2 diabetes through the disruption of circadian rhythms, for example as a result of shift work.
We are also evaluating the use of low carbohydrate diets in patients with T2D and assessing how they interact with the metabolism.
In the past we have conducted a number of studies to better understand and devise treatments for type 2 diabetes, including total diet replacement, low carbohydrate diets, drug and digital support. We are using data and clinical samples from these studies – as well as ongoing large-scale cardiovascular trials EXSCEL and TECOS – to identify factors that might indicate how a patient will respond to different treatments and how complications might develop.
The NewDAWN project led by Professor Susan Jebb ran from May 2022 to June 2025, and aimed to develop and test a new pathway to support more people to achieve remission of type 2 diabetes. The team carried out extensive development work, working with diverse groups of people living with type 2 diabetes to ensure that the pathway meets their needs. This work is now being integrated into training for healthcare providers by Diabetes UK. The trial to test the new pathway did not go ahead largely because Path to Remission was rolled out more quickly and more widely than anticipated.